Search
for

    Glossary Metyrapone

    Metyrapone is a medication primarily used to test adrenal function by inhibiting the enzyme 11β-hydroxylase, which is involved in cortisol synthesis. Its relevance to hair loss lies in its potential effects on hormonal balance, particularly cortisol levels, which can influence hair growth and loss. Elevated cortisol levels are often associated with stress-related hair loss conditions, making metyrapone a point of interest in understanding the hormonal pathways that affect hair biology. Key distinguishing characteristics include its role in diagnosing adrenal insufficiency and its impact on steroid metabolism.

    Research 10 of 58

    1. METYRAPONE AS A BRIDGING THERAPY IN FLORID CUSHING’S DISEASE PATIENT PRIOR TO PITUITARY ADENOMECTOMY Journal of the ASEAN Federation of Endocrine Societies · 2023
    2. Role of GABA-active neurosteroids in the efficacy of metyrapone against cocaine addiction Behavioural Brain Research · 2014 · 15 citations
    3. Persistent escalation of alcohol consumption by mice exposed to brief episodes of social defeat stress: suppression by CRF-R1 antagonism 2018 · 38 citations
    4. 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis Neuropharmacology · 2011 · 18 citations
    5. Hydroxylation of dehydroepiandrosterone in human scalp hair folhcles British Journal of Dermatology · 1979 · 11 citations
    6. Transient treatment of pregnant Merino ewes with modulators of cortisol biosynthesis coinciding with primary wool follicle initiation alters lifetime wool growth Animal Production Science · 2013 · 7 citations
    7. Role of neurosteroids in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked neuronal injury and behavioral deficits in mice Der pharmacia lettre · 2015 · 1 citations
    8. P-50 WE KNOW YOU ARE THERE: MISSING MASS JCEM Case Reports · 2025
    9. PSAT001 A Case of Ectopic Cushing's Syndrome Complicated by COVID-19 Infection Journal of the Endocrine Society · 2022
    10. SAT-271 Block and Replace Therapy Successfully Improved Symptoms in Recurrent Cyclic Cushing’s Disease Journal of the Endocrine Society · 2020
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →